Second Sight Medical Products, Inc. (EYES) Stock Competitors & Peer Comparison
See (EYES) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EYES | $4.14 | -5.05% | 210M | N/A | N/A | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $87.02 | +0.06% | 151.5B | 24.37 | $3.57 | +2.80% |
| ISRG | $407.29 | +1.24% | 144.2B | 49.37 | $8.25 | N/A |
| SYK | $295.00 | +0.58% | 113.1B | 34.11 | $8.65 | +1.17% |
| MDT | $77.95 | +5.69% | 100.2B | 21.80 | $3.58 | +3.66% |
| BSX | $47.69 | +0.02% | 70.9B | 19.96 | $2.39 | N/A |
| BRKRP | $463.61 | +8.34% | 70.4B | N/A | N/A | +0.33% |
| EW | $86.00 | -1.89% | 49.5B | 46.51 | $1.85 | N/A |
| DXCM | $72.77 | -0.93% | 28.1B | 31.23 | $2.33 | N/A |
Stock Comparison
EYES vs BSX-PA Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, EYES is priced at $4.14, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, EYES's ROE is -2.64%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, EYES is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check BSX-PA's competition here
EYES vs ABT Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, ABT has a market cap of 151.5B. Regarding current trading prices, EYES is priced at $4.14, while ABT trades at $87.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas ABT's P/E ratio is 24.37. In terms of profitability, EYES's ROE is -2.64%, compared to ABT's ROE of +0.12%. Regarding short-term risk, EYES is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check ABT's competition here
EYES vs ISRG Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, ISRG has a market cap of 144.2B. Regarding current trading prices, EYES is priced at $4.14, while ISRG trades at $407.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas ISRG's P/E ratio is 49.37. In terms of profitability, EYES's ROE is -2.64%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, EYES is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check ISRG's competition here
EYES vs SYK Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, SYK has a market cap of 113.1B. Regarding current trading prices, EYES is priced at $4.14, while SYK trades at $295.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas SYK's P/E ratio is 34.11. In terms of profitability, EYES's ROE is -2.64%, compared to SYK's ROE of +0.15%. Regarding short-term risk, EYES is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check SYK's competition here
EYES vs MDT Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, MDT has a market cap of 100.2B. Regarding current trading prices, EYES is priced at $4.14, while MDT trades at $77.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas MDT's P/E ratio is 21.80. In terms of profitability, EYES's ROE is -2.64%, compared to MDT's ROE of +0.10%. Regarding short-term risk, EYES is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check MDT's competition here
EYES vs BSX Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, BSX has a market cap of 70.9B. Regarding current trading prices, EYES is priced at $4.14, while BSX trades at $47.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas BSX's P/E ratio is 19.96. In terms of profitability, EYES's ROE is -2.64%, compared to BSX's ROE of +0.15%. Regarding short-term risk, EYES is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check BSX's competition here
EYES vs BRKRP Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, BRKRP has a market cap of 70.4B. Regarding current trading prices, EYES is priced at $4.14, while BRKRP trades at $463.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas BRKRP's P/E ratio is N/A. In terms of profitability, EYES's ROE is -2.64%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, EYES is less volatile compared to BRKRP. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check BRKRP's competition here
EYES vs EW Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, EW has a market cap of 49.5B. Regarding current trading prices, EYES is priced at $4.14, while EW trades at $86.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas EW's P/E ratio is 46.51. In terms of profitability, EYES's ROE is -2.64%, compared to EW's ROE of +0.11%. Regarding short-term risk, EYES is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check EW's competition here
EYES vs DXCM Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, DXCM has a market cap of 28.1B. Regarding current trading prices, EYES is priced at $4.14, while DXCM trades at $72.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas DXCM's P/E ratio is 31.23. In terms of profitability, EYES's ROE is -2.64%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, EYES is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check DXCM's competition here
EYES vs RMD Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, RMD has a market cap of 27.1B. Regarding current trading prices, EYES is priced at $4.14, while RMD trades at $186.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas RMD's P/E ratio is 17.98. In terms of profitability, EYES's ROE is -2.64%, compared to RMD's ROE of +0.24%. Regarding short-term risk, EYES is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check RMD's competition here
EYES vs PHG Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, PHG has a market cap of 24.1B. Regarding current trading prices, EYES is priced at $4.14, while PHG trades at $25.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas PHG's P/E ratio is 21.86. In terms of profitability, EYES's ROE is -2.64%, compared to PHG's ROE of +0.09%. Regarding short-term risk, EYES is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check PHG's competition here
EYES vs STE Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, STE has a market cap of 20.6B. Regarding current trading prices, EYES is priced at $4.14, while STE trades at $210.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas STE's P/E ratio is 26.52. In terms of profitability, EYES's ROE is -2.64%, compared to STE's ROE of +0.11%. Regarding short-term risk, EYES is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check STE's competition here
EYES vs ABMD Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, EYES is priced at $4.14, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas ABMD's P/E ratio is 65.36. In terms of profitability, EYES's ROE is -2.64%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, EYES is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check ABMD's competition here
EYES vs ZBH Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, ZBH has a market cap of 16.4B. Regarding current trading prices, EYES is priced at $4.14, while ZBH trades at $84.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas ZBH's P/E ratio is 22.02. In terms of profitability, EYES's ROE is -2.64%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, EYES is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check ZBH's competition here
EYES vs SNN Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, SNN has a market cap of 12.7B. Regarding current trading prices, EYES is priced at $4.14, while SNN trades at $29.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas SNN's P/E ratio is 20.93. In terms of profitability, EYES's ROE is -2.64%, compared to SNN's ROE of +0.12%. Regarding short-term risk, EYES is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check SNN's competition here
EYES vs SWAV Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, EYES is priced at $4.14, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas SWAV's P/E ratio is 78.76. In terms of profitability, EYES's ROE is -2.64%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, EYES is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check SWAV's competition here
EYES vs PEN Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, EYES is priced at $4.14, while PEN trades at $319.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas PEN's P/E ratio is 73.76. In terms of profitability, EYES's ROE is -2.64%, compared to PEN's ROE of +0.12%. Regarding short-term risk, EYES is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check PEN's competition here
EYES vs ALGN Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, ALGN has a market cap of 11.6B. Regarding current trading prices, EYES is priced at $4.14, while ALGN trades at $161.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas ALGN's P/E ratio is 27.22. In terms of profitability, EYES's ROE is -2.64%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, EYES is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check ALGN's competition here
EYES vs GMED Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, GMED has a market cap of 10.5B. Regarding current trading prices, EYES is priced at $4.14, while GMED trades at $77.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas GMED's P/E ratio is 18.21. In terms of profitability, EYES's ROE is -2.64%, compared to GMED's ROE of +0.13%. Regarding short-term risk, EYES is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check GMED's competition here
EYES vs PODD Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, PODD has a market cap of 9.9B. Regarding current trading prices, EYES is priced at $4.14, while PODD trades at $143.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas PODD's P/E ratio is 33.48. In terms of profitability, EYES's ROE is -2.64%, compared to PODD's ROE of +0.21%. Regarding short-term risk, EYES is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check PODD's competition here
EYES vs BRKR Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, BRKR has a market cap of 9.5B. Regarding current trading prices, EYES is priced at $4.14, while BRKR trades at $62.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas BRKR's P/E ratio is -261.25. In terms of profitability, EYES's ROE is -2.64%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, EYES is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check BRKR's competition here
EYES vs MASI Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, EYES is priced at $4.14, while MASI trades at $178.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas MASI's P/E ratio is 44.36. In terms of profitability, EYES's ROE is -2.64%, compared to MASI's ROE of +0.09%. Regarding short-term risk, EYES is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check MASI's competition here
EYES vs BIO-B Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, BIO-B has a market cap of 8.2B. Regarding current trading prices, EYES is priced at $4.14, while BIO-B trades at $304.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas BIO-B's P/E ratio is 50.64. In terms of profitability, EYES's ROE is -2.64%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, EYES is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check BIO-B's competition here
EYES vs BIO Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, BIO has a market cap of 8.2B. Regarding current trading prices, EYES is priced at $4.14, while BIO trades at $304.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas BIO's P/E ratio is 50.60. In terms of profitability, EYES's ROE is -2.64%, compared to BIO's ROE of +0.02%. Regarding short-term risk, EYES is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check BIO's competition here
EYES vs GKOS Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, GKOS has a market cap of 6.7B. Regarding current trading prices, EYES is priced at $4.14, while GKOS trades at $113.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas GKOS's P/E ratio is -34.45. In terms of profitability, EYES's ROE is -2.64%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, EYES is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check GKOS's competition here
EYES vs NARI Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, EYES is priced at $4.14, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas NARI's P/E ratio is -59.24. In terms of profitability, EYES's ROE is -2.64%, compared to NARI's ROE of -0.00%. Regarding short-term risk, EYES is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check NARI's competition here
EYES vs LIVN Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, LIVN has a market cap of 3.9B. Regarding current trading prices, EYES is priced at $4.14, while LIVN trades at $71.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas LIVN's P/E ratio is 36.39. In terms of profitability, EYES's ROE is -2.64%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, EYES is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check LIVN's competition here
EYES vs AXNX Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, EYES is priced at $4.14, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas AXNX's P/E ratio is -709.80. In terms of profitability, EYES's ROE is -2.64%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, EYES is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check AXNX's competition here
EYES vs IRTC Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, IRTC has a market cap of 3.4B. Regarding current trading prices, EYES is priced at $4.14, while IRTC trades at $104.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas IRTC's P/E ratio is -123.01. In terms of profitability, EYES's ROE is -2.64%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, EYES is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check IRTC's competition here
EYES vs ITGR Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, ITGR has a market cap of 3.1B. Regarding current trading prices, EYES is priced at $4.14, while ITGR trades at $90.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas ITGR's P/E ratio is 22.56. In terms of profitability, EYES's ROE is -2.64%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, EYES is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check ITGR's competition here
EYES vs TMDX Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, TMDX has a market cap of 2.4B. Regarding current trading prices, EYES is priced at $4.14, while TMDX trades at $69.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas TMDX's P/E ratio is 15.95. In terms of profitability, EYES's ROE is -2.64%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, EYES is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check TMDX's competition here
EYES vs AXGN Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, AXGN has a market cap of 2.2B. Regarding current trading prices, EYES is priced at $4.14, while AXGN trades at $40.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas AXGN's P/E ratio is -63.48. In terms of profitability, EYES's ROE is -2.64%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, EYES is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check AXGN's competition here
EYES vs ESTA Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, ESTA has a market cap of 2.1B. Regarding current trading prices, EYES is priced at $4.14, while ESTA trades at $72.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas ESTA's P/E ratio is -49.26. In terms of profitability, EYES's ROE is -2.64%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, EYES is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check ESTA's competition here
EYES vs NUVA Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, EYES is priced at $4.14, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas NUVA's P/E ratio is 75.00. In terms of profitability, EYES's ROE is -2.64%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, EYES is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check NUVA's competition here
EYES vs UFPT Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, EYES is priced at $4.14, while UFPT trades at $218.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas UFPT's P/E ratio is 24.84. In terms of profitability, EYES's ROE is -2.64%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, EYES is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check UFPT's competition here
EYES vs PRCT Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, PRCT has a market cap of 1.5B. Regarding current trading prices, EYES is priced at $4.14, while PRCT trades at $26.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas PRCT's P/E ratio is -14.39. In terms of profitability, EYES's ROE is -2.64%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, EYES is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check PRCT's competition here
EYES vs AHCO Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, EYES is priced at $4.14, while AHCO trades at $9.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas AHCO's P/E ratio is -16.47. In terms of profitability, EYES's ROE is -2.64%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, EYES is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check AHCO's competition here
EYES vs HSKA Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, EYES is priced at $4.14, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas HSKA's P/E ratio is -62.49. In terms of profitability, EYES's ROE is -2.64%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, EYES is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check HSKA's competition here
EYES vs IART Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, EYES is priced at $4.14, while IART trades at $16.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas IART's P/E ratio is -2.49. In terms of profitability, EYES's ROE is -2.64%, compared to IART's ROE of -0.48%. Regarding short-term risk, EYES is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check IART's competition here
EYES vs ENOV Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, ENOV has a market cap of 1.2B. Regarding current trading prices, EYES is priced at $4.14, while ENOV trades at $21.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas ENOV's P/E ratio is -1.08. In terms of profitability, EYES's ROE is -2.64%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, EYES is more volatile compared to ENOV. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check ENOV's competition here
EYES vs TNDM Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, TNDM has a market cap of 1.2B. Regarding current trading prices, EYES is priced at $4.14, while TNDM trades at $18.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas TNDM's P/E ratio is -13.16. In terms of profitability, EYES's ROE is -2.64%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, EYES is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check TNDM's competition here
EYES vs ATEC Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, ATEC has a market cap of 1.2B. Regarding current trading prices, EYES is priced at $4.14, while ATEC trades at $7.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas ATEC's P/E ratio is -9.25. In terms of profitability, EYES's ROE is -2.64%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, EYES is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check ATEC's competition here
EYES vs AVNS Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, EYES is priced at $4.14, while AVNS trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas AVNS's P/E ratio is -15.60. In terms of profitability, EYES's ROE is -2.64%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, EYES is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check AVNS's competition here
EYES vs INSP Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, INSP has a market cap of 1.2B. Regarding current trading prices, EYES is priced at $4.14, while INSP trades at $40.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas INSP's P/E ratio is 9.20. In terms of profitability, EYES's ROE is -2.64%, compared to INSP's ROE of +0.18%. Regarding short-term risk, EYES is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check INSP's competition here
EYES vs IRMD Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, EYES is priced at $4.14, while IRMD trades at $91.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas IRMD's P/E ratio is 49.79. In terms of profitability, EYES's ROE is -2.64%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, EYES is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check IRMD's competition here
EYES vs BFLY Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, BFLY has a market cap of 1.1B. Regarding current trading prices, EYES is priced at $4.14, while BFLY trades at $4.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas BFLY's P/E ratio is -14.65. In terms of profitability, EYES's ROE is -2.64%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, EYES is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check BFLY's competition here
EYES vs SILK Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, EYES is priced at $4.14, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas SILK's P/E ratio is -18.96. In terms of profitability, EYES's ROE is -2.64%, compared to SILK's ROE of -0.35%. Regarding short-term risk, EYES is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check SILK's competition here
EYES vs FNA Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, EYES is priced at $4.14, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas FNA's P/E ratio is -19.83. In terms of profitability, EYES's ROE is -2.64%, compared to FNA's ROE of -0.35%. Regarding short-term risk, EYES is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check FNA's competition here
EYES vs AORT Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, AORT has a market cap of 999.3M. Regarding current trading prices, EYES is priced at $4.14, while AORT trades at $20.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas AORT's P/E ratio is 82.34. In terms of profitability, EYES's ROE is -2.64%, compared to AORT's ROE of +0.03%. Regarding short-term risk, EYES is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check AORT's competition here
EYES vs CNMD Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, CNMD has a market cap of 996.5M. Regarding current trading prices, EYES is priced at $4.14, while CNMD trades at $33.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas CNMD's P/E ratio is 18.70. In terms of profitability, EYES's ROE is -2.64%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, EYES is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check CNMD's competition here
EYES vs SSII Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, SSII has a market cap of 862.6M. Regarding current trading prices, EYES is priced at $4.14, while SSII trades at $4.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas SSII's P/E ratio is -86.20. In terms of profitability, EYES's ROE is -2.64%, compared to SSII's ROE of -0.23%. Regarding short-term risk, EYES is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check SSII's competition here
EYES vs INMD Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, INMD has a market cap of 854.7M. Regarding current trading prices, EYES is priced at $4.14, while INMD trades at $13.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas INMD's P/E ratio is 9.99. In terms of profitability, EYES's ROE is -2.64%, compared to INMD's ROE of +0.13%. Regarding short-term risk, EYES is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check INMD's competition here
EYES vs CSII Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, EYES is priced at $4.14, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas CSII's P/E ratio is -20.83. In terms of profitability, EYES's ROE is -2.64%, compared to CSII's ROE of -0.14%. Regarding short-term risk, EYES is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check CSII's competition here
EYES vs LMRI Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, LMRI has a market cap of 746.5M. Regarding current trading prices, EYES is priced at $4.14, while LMRI trades at $7.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas LMRI's P/E ratio is -19.92. In terms of profitability, EYES's ROE is -2.64%, compared to LMRI's ROE of -0.15%. Regarding short-term risk, EYES is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check LMRI's competition here
EYES vs CRY Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, EYES is priced at $4.14, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas CRY's P/E ratio is 425.71. In terms of profitability, EYES's ROE is -2.64%, compared to CRY's ROE of +0.03%. Regarding short-term risk, EYES is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check CRY's competition here
EYES vs CBLL Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, CBLL has a market cap of 651.9M. Regarding current trading prices, EYES is priced at $4.14, while CBLL trades at $17.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas CBLL's P/E ratio is -10.60. In terms of profitability, EYES's ROE is -2.64%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, EYES is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check CBLL's competition here
EYES vs SIBN Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, SIBN has a market cap of 617.3M. Regarding current trading prices, EYES is priced at $4.14, while SIBN trades at $13.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas SIBN's P/E ratio is -35.69. In terms of profitability, EYES's ROE is -2.64%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, EYES is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check SIBN's competition here
EYES vs SRDX Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, EYES is priced at $4.14, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas SRDX's P/E ratio is -34.66. In terms of profitability, EYES's ROE is -2.64%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, EYES is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check SRDX's competition here
EYES vs APEN Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, EYES is priced at $4.14, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas APEN's P/E ratio is -9.43. In terms of profitability, EYES's ROE is -2.64%, compared to APEN's ROE of -0.85%. Regarding short-term risk, EYES is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check APEN's competition here
EYES vs BVS Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, BVS has a market cap of 579.2M. Regarding current trading prices, EYES is priced at $4.14, while BVS trades at $8.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas BVS's P/E ratio is 20.85. In terms of profitability, EYES's ROE is -2.64%, compared to BVS's ROE of +0.16%. Regarding short-term risk, EYES is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check BVS's competition here
EYES vs BWAY Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, BWAY has a market cap of 550.7M. Regarding current trading prices, EYES is priced at $4.14, while BWAY trades at $14.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas BWAY's P/E ratio is 63.82. In terms of profitability, EYES's ROE is -2.64%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, EYES is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check BWAY's competition here
EYES vs TCMD Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, TCMD has a market cap of 549.7M. Regarding current trading prices, EYES is priced at $4.14, while TCMD trades at $24.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas TCMD's P/E ratio is 28.01. In terms of profitability, EYES's ROE is -2.64%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, EYES is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check TCMD's competition here
EYES vs NPCE Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, NPCE has a market cap of 541.4M. Regarding current trading prices, EYES is priced at $4.14, while NPCE trades at $15.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas NPCE's P/E ratio is -24.43. In terms of profitability, EYES's ROE is -2.64%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, EYES is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check NPCE's competition here
EYES vs ZIMV Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, EYES is priced at $4.14, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, EYES's ROE is -2.64%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, EYES is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check ZIMV's competition here
EYES vs CERS Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, CERS has a market cap of 533M. Regarding current trading prices, EYES is priced at $4.14, while CERS trades at $2.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas CERS's P/E ratio is -53.20. In terms of profitability, EYES's ROE is -2.64%, compared to CERS's ROE of -0.15%. Regarding short-term risk, EYES is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check CERS's competition here
EYES vs CTKB Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, CTKB has a market cap of 523M. Regarding current trading prices, EYES is priced at $4.14, while CTKB trades at $4.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas CTKB's P/E ratio is -6.98. In terms of profitability, EYES's ROE is -2.64%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, EYES is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check CTKB's competition here
EYES vs PACB Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, PACB has a market cap of 490.8M. Regarding current trading prices, EYES is priced at $4.14, while PACB trades at $1.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas PACB's P/E ratio is -3.85. In terms of profitability, EYES's ROE is -2.64%, compared to PACB's ROE of -4.88%. Regarding short-term risk, EYES is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check PACB's competition here
EYES vs PMI Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, PMI has a market cap of 476.9M. Regarding current trading prices, EYES is priced at $4.14, while PMI trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas PMI's P/E ratio is -0.40. In terms of profitability, EYES's ROE is -2.64%, compared to PMI's ROE of +4.99%. Regarding short-term risk, EYES is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check PMI's competition here
EYES vs LAB Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, LAB has a market cap of 445M. Regarding current trading prices, EYES is priced at $4.14, while LAB trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas LAB's P/E ratio is -8.77. In terms of profitability, EYES's ROE is -2.64%, compared to LAB's ROE of -0.21%. Regarding short-term risk, EYES is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check LAB's competition here
EYES vs KIDS Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, KIDS has a market cap of 434.6M. Regarding current trading prices, EYES is priced at $4.14, while KIDS trades at $16.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas KIDS's P/E ratio is -10.07. In terms of profitability, EYES's ROE is -2.64%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, EYES is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check KIDS's competition here
EYES vs VREX Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, VREX has a market cap of 427.7M. Regarding current trading prices, EYES is priced at $4.14, while VREX trades at $10.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas VREX's P/E ratio is -5.08. In terms of profitability, EYES's ROE is -2.64%, compared to VREX's ROE of -0.18%. Regarding short-term risk, EYES is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check VREX's competition here
EYES vs CLPT Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, CLPT has a market cap of 398.9M. Regarding current trading prices, EYES is priced at $4.14, while CLPT trades at $13.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas CLPT's P/E ratio is -13.30. In terms of profitability, EYES's ROE is -2.64%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, EYES is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check CLPT's competition here
EYES vs OFIX Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, OFIX has a market cap of 392.9M. Regarding current trading prices, EYES is priced at $4.14, while OFIX trades at $9.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas OFIX's P/E ratio is -6.48. In terms of profitability, EYES's ROE is -2.64%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, EYES is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check OFIX's competition here
EYES vs VMD Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, VMD has a market cap of 366.5M. Regarding current trading prices, EYES is priced at $4.14, while VMD trades at $9.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas VMD's P/E ratio is 25.84. In terms of profitability, EYES's ROE is -2.64%, compared to VMD's ROE of +0.11%. Regarding short-term risk, EYES is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check VMD's competition here
EYES vs DCTH Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, DCTH has a market cap of 356.6M. Regarding current trading prices, EYES is priced at $4.14, while DCTH trades at $10.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas DCTH's P/E ratio is 1033.00. In terms of profitability, EYES's ROE is -2.64%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, EYES is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check DCTH's competition here
EYES vs AVR Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, AVR has a market cap of 329.3M. Regarding current trading prices, EYES is priced at $4.14, while AVR trades at $8.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas AVR's P/E ratio is -4.03. In terms of profitability, EYES's ROE is -2.64%, compared to AVR's ROE of -1.24%. Regarding short-term risk, EYES is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check AVR's competition here
EYES vs MASS Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, MASS has a market cap of 327.5M. Regarding current trading prices, EYES is priced at $4.14, while MASS trades at $8.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas MASS's P/E ratio is -8.93. In terms of profitability, EYES's ROE is -2.64%, compared to MASS's ROE of -0.26%. Regarding short-term risk, EYES is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check MASS's competition here
EYES vs SMLR Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, EYES is priced at $4.14, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas SMLR's P/E ratio is 3.92. In terms of profitability, EYES's ROE is -2.64%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, EYES is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check SMLR's competition here
EYES vs ELMD Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, ELMD has a market cap of 296.1M. Regarding current trading prices, EYES is priced at $4.14, while ELMD trades at $35.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas ELMD's P/E ratio is 30.56. In terms of profitability, EYES's ROE is -2.64%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, EYES is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check ELMD's competition here
EYES vs SENS Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, SENS has a market cap of 280.7M. Regarding current trading prices, EYES is priced at $4.14, while SENS trades at $6.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas SENS's P/E ratio is -3.41. In terms of profitability, EYES's ROE is -2.64%, compared to SENS's ROE of -1.30%. Regarding short-term risk, EYES is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check SENS's competition here
EYES vs CATX Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, CATX has a market cap of 273.5M. Regarding current trading prices, EYES is priced at $4.14, while CATX trades at $3.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas CATX's P/E ratio is -2.51. In terms of profitability, EYES's ROE is -2.64%, compared to CATX's ROE of -0.42%. Regarding short-term risk, EYES is more volatile compared to CATX. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check CATX's competition here
EYES vs MGRM Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, EYES is priced at $4.14, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas MGRM's P/E ratio is -11.11. In terms of profitability, EYES's ROE is -2.64%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, EYES is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check MGRM's competition here
EYES vs SGHT Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, SGHT has a market cap of 236.1M. Regarding current trading prices, EYES is priced at $4.14, while SGHT trades at $4.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas SGHT's P/E ratio is -6.20. In terms of profitability, EYES's ROE is -2.64%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, EYES is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check SGHT's competition here
EYES vs NVRO Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, EYES is priced at $4.14, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas NVRO's P/E ratio is -1.91. In terms of profitability, EYES's ROE is -2.64%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, EYES is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check NVRO's competition here
EYES vs TMCI Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, TMCI has a market cap of 220.6M. Regarding current trading prices, EYES is priced at $4.14, while TMCI trades at $3.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas TMCI's P/E ratio is -3.54. In terms of profitability, EYES's ROE is -2.64%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, EYES is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check TMCI's competition here
EYES vs RXST Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, RXST has a market cap of 198.3M. Regarding current trading prices, EYES is priced at $4.14, while RXST trades at $4.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas RXST's P/E ratio is -4.24. In terms of profitability, EYES's ROE is -2.64%, compared to RXST's ROE of -0.17%. Regarding short-term risk, EYES is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check RXST's competition here
EYES vs PROF Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, PROF has a market cap of 198.2M. Regarding current trading prices, EYES is priced at $4.14, while PROF trades at $6.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas PROF's P/E ratio is -5.28. In terms of profitability, EYES's ROE is -2.64%, compared to PROF's ROE of -0.71%. Regarding short-term risk, EYES is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check PROF's competition here
EYES vs ANIK Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, ANIK has a market cap of 191.7M. Regarding current trading prices, EYES is priced at $4.14, while ANIK trades at $14.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas ANIK's P/E ratio is -18.24. In terms of profitability, EYES's ROE is -2.64%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, EYES is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check ANIK's competition here
EYES vs BSGM Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, EYES is priced at $4.14, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas BSGM's P/E ratio is -5.81. In terms of profitability, EYES's ROE is -2.64%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, EYES is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check BSGM's competition here
EYES vs MDGS Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, EYES is priced at $4.14, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas MDGS's P/E ratio is -0.27. In terms of profitability, EYES's ROE is -2.64%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, EYES is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check MDGS's competition here
EYES vs EDAP Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, EDAP has a market cap of 178.2M. Regarding current trading prices, EYES is priced at $4.14, while EDAP trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas EDAP's P/E ratio is -5.80. In terms of profitability, EYES's ROE is -2.64%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, EYES is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check EDAP's competition here
EYES vs QTRX Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, QTRX has a market cap of 166.3M. Regarding current trading prices, EYES is priced at $4.14, while QTRX trades at $3.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas QTRX's P/E ratio is -1.50. In terms of profitability, EYES's ROE is -2.64%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, EYES is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check QTRX's competition here
EYES vs QIPT Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, EYES is priced at $4.14, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas QIPT's P/E ratio is -15.87. In terms of profitability, EYES's ROE is -2.64%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, EYES is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check QIPT's competition here
EYES vs INGN Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, INGN has a market cap of 161.9M. Regarding current trading prices, EYES is priced at $4.14, while INGN trades at $5.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas INGN's P/E ratio is -6.57. In terms of profitability, EYES's ROE is -2.64%, compared to INGN's ROE of -0.13%. Regarding short-term risk, EYES is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check INGN's competition here
EYES vs APYX Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, APYX has a market cap of 158.7M. Regarding current trading prices, EYES is priced at $4.14, while APYX trades at $3.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas APYX's P/E ratio is -17.23. In terms of profitability, EYES's ROE is -2.64%, compared to APYX's ROE of -0.91%. Regarding short-term risk, EYES is more volatile compared to APYX. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check APYX's competition here
EYES vs CVRX Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, CVRX has a market cap of 143M. Regarding current trading prices, EYES is priced at $4.14, while CVRX trades at $5.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas CVRX's P/E ratio is -2.68. In terms of profitability, EYES's ROE is -2.64%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, EYES is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for EYES.Check CVRX's competition here
EYES vs SNWV Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, SNWV has a market cap of 134.1M. Regarding current trading prices, EYES is priced at $4.14, while SNWV trades at $15.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas SNWV's P/E ratio is 16.25. In terms of profitability, EYES's ROE is -2.64%, compared to SNWV's ROE of -4.51%. Regarding short-term risk, EYES is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check SNWV's competition here
EYES vs NNOX Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, NNOX has a market cap of 130.1M. Regarding current trading prices, EYES is priced at $4.14, while NNOX trades at $1.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas NNOX's P/E ratio is -1.61. In terms of profitability, EYES's ROE is -2.64%, compared to NNOX's ROE of -0.47%. Regarding short-term risk, EYES is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check NNOX's competition here
EYES vs MXCT Comparison June 2026
EYES plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EYES stands at 210M. In comparison, MXCT has a market cap of 128.5M. Regarding current trading prices, EYES is priced at $4.14, while MXCT trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EYES currently has a P/E ratio of N/A, whereas MXCT's P/E ratio is -3.33. In terms of profitability, EYES's ROE is -2.64%, compared to MXCT's ROE of -0.22%. Regarding short-term risk, EYES is less volatile compared to MXCT. This indicates potentially lower risk in terms of short-term price fluctuations for EYES.Check MXCT's competition here